Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CETP | P11597 | 4/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25657182 | 0.86 | TSHR (0.64) | TSHRCETPSRCFOLH1PDPK1 | |
| SCHEMBL11538617 | 0.83 | TSHR (0.70) | TSHRCETPSRCFOLH1PDPK1 | |
| SCHEMBL19751901 | 0.82 | TSHR (0.63) | TSHRCETPSRCFOLH1PDPK1 | |
| Alcohol SCHEMBL6037288 | 0.81 | TSHR (0.85) | TSHRCETPSRCFOLH1PDPK1 | |
| SCHEMBL25657144 | 0.81 | TSHR (0.66) | TSHRCETPSRCFOLH1PDPK1 | |
| SCHEMBL51316 | 0.80 | TSHR (1.00) | TSHRCETPSRCFOLH1PDPK1 | |
| SCHEMBL27908642 | 0.80 | TSHR (1.00) | TSHRCETPSRCFOLH1PDPK1 | |
| SCHEMBL1404249 | 0.80 | TSHR (0.81) | TSHRCETPSRCFOLH1PDPK1 | |
| SCHEMBL9446520 | 0.79 | TSHR (0.96) | TSHRCETPSRCFOLH1PDPK1 | |
| Ammonia Solution, Strong SCHEMBL7268743 | 0.79 | TSHR (0.96) | TSHRCETPSRCFOLH1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214569-B2 | Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof | LENZ THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200181136-A1 | Prodrugs of Quinuclidine Ring-containing Muscarinic Agonists and Compositions and Methods Thereof | LENZ THERAPEUTICS OPERATIONS, INC. | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214569-B2 | Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof | CHRM3, CHRM2, CHRM5 | TSHR 1126/4885CETP 757/4885SRC 3756/4885 |
| US-20200181136-A1 | Prodrugs of Quinuclidine Ring-containing Muscarinic Agonists and Compositions and Methods Thereof | CHRM3, CHRM2, CHRM5 | TSHR 1130/4885CETP 1136/4885SRC 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.